AstraZeneca (AZN) Leading In Pre-Market Activity
Trade-Ideas LLC identified
(
) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified AstraZeneca as such a stock due to the following factors:
- AZN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $271.3 million.
- AZN traded 10,454 shares today in the pre-market hours as of 8:06 AM.
- AZN is up 2.6% today from yesterday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in AZN with the Ticky from Trade-Ideas. See the FREE profile for AZN NOW at Trade-Ideas
More details on AZN:
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide. The stock currently has a dividend yield of 4.4%. AZN has a PE ratio of 14. Currently there is 1 analyst that rates AstraZeneca a buy, no analysts rate it a sell, and 3 rate it a hold.
The average volume for AstraZeneca has been 5.2 million shares per day over the past 30 days. AstraZeneca has a market cap of $78.8 billion and is part of the health care sector and drugs industry. Shares are down 8.9% year-to-date as of the close of trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates AstraZeneca as a
. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
Highlights from the ratings report include:
- ASTRAZENECA PLC has improved earnings per share by 18.2% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, ASTRAZENECA PLC increased its bottom line by earning $1.12 versus $0.49 in the prior year. This year, the market expects an improvement in earnings ($2.00 versus $1.12).
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Pharmaceuticals industry average. The net income increased by 17.4% when compared to the same quarter one year prior, going from $550.00 million to $646.00 million.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. In comparison to the other companies in the Pharmaceuticals industry and the overall market, ASTRAZENECA PLC's return on equity significantly exceeds that of the industry average and is above that of the S&P 500.
- Net operating cash flow has significantly increased by 1756.94% to $1,193.00 million when compared to the same quarter last year. In addition, ASTRAZENECA PLC has also vastly surpassed the industry average cash flow growth rate of -54.38%.
- You can view the full AstraZeneca Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.